Long-term treatment with long-acting risperidone in Korean patients with schizophrenia

Human Psychopharmacology

Volumn 21, Issue 6, 2006, Pages 399-407

  Lee, Moon Soo ^a   Ko, Young Hoon ^a   Lee, Sang Hoon ^a   Seo, Yong Jin ^b   Kim, Seung Hyun ^a   Joe, Sook Haeng ^a   Han, Chang Su ^a   Lee, Jung Ho ^c   Jung, In Kwa ^a  

^a Korea University College of Medicine   (South Korea)

^b Yong In Psychiat Research Institute   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

Long acting injection risperidone; PANSS; Perceived functioning; Schizophrenia; Well being

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; LONG ACTING DRUG; OLANZAPINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; AGED; ARTICLE; BLURRED VISION; BODY WEIGHT DISORDER; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED EXTRAPYRAMIDAL SYMPTOM SCALE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FUNCTIONAL ASSESSMENT; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; INSOMNIA; KOREA; MALE; MENSTRUAL IRREGULARITY; OCULOGYRIC CRISIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SHORT FORM 36; SUBJECTIVE WELLBEING UNDER NEUROLEPTIC TREATMENT SCALE; WEIGHT GAIN; WELLBEING;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748490089     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.782     Document Type: Article

References (31)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, American Psychiatric Association: Washington, DC.
2. Anonymous. 1995. Quality of life and clinical trials. Lancet 346: 1-2.
3. Bhanji NH, Chouinard G, Margolese HC. 2004. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 14: 87-92.
4. Bullinger M, Hasford J. 1991. Evaluating quality-of-life measures for clinical trials in Germany. Control Clin Trials 12: S91-S105.
5. Chung S, Cho S-J, Kim C-H, et al. 2005. Effectiveness and tolerability of long-acting RIsperidone: A 12 weeks, multi-center switching study from oral antipsychotics. Korean J Psychopharmacol 16: 109-120.
6. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. 1994. Depot antipsychotic drugs. Place in therapy. Drugs 47: 741-773.
7. Fleischhacker WW, Eerdekens M, Karcher K, et al. 2003. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257.
8. Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. 2005. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 187: 131-136.
9. Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER. 2005. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 19: 32-38.
10. Hogan TP, Awad AG, Eastwood R. 1983. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13: 177-183.
11. Kane JM. 2003. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 64(Suppl. 16): S34-S40.
12. Kane JM, Aguglia E, Altamura AC, et al. 1998. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8: 55-66.
13. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. 2003. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132.
14. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
15. Koh SB, Chang SJ, Kang MG, Cha BS, Park JK. 1997. Reliability and validity on measurement instrument for health status assessment in occupational workers. Korean J Prev Med Public Health 30: 251-266.
16. Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M. 2004. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry 19: 898-905.
17. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. 2005. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 77: 215-227.
18. Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. 2005. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 72: 249-258.
19. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. 2004. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65: 1084-1089.
20. Lindenmayer JP, Jarboe K, Bossie CA, Zhu Y, Mehnert A, Lasser R. 2005. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 20: 213-221.
21. Meltzer HY. 2004. Cognitive factors in schizophrenia: Causes, impact, and treatment. CNS Spectr 9: 15-24.
22. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. 2005. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20: 121-130.
23. Naber D. 1995. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10(Suppl. 3): S133-S138.
24. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. 2004. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 65: 531-536.
25. Robinson D, Woerner MG, Alvir JM, et al. 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241-247.
26. Siegel SJ, Irani F, Brensinger CM, et al. 2006. Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry 163: 433-441.
27. Taylor M, Chaudhry I, Cross M, et al. 2005. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol 20: 175-181.
28. Tulloch AD, Fearon P, David AS. 2006. Social outcomes in schizophrenia: from description to action. Curr Opin Psychiatry 19: 140-144.
29. Guy W. 1976. Clinical Global Impression. Department of Health, Education, and Welfare: Rockville, Maryland.
30. Ware JE, Jr., Sherbourne CD. 1992. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483.
31. Zhang PL, Santos JM, Newcomer J, Pelfrey BA, Johnson MC, de Erausquin GA. 2004. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res 71: 137-144.